CCL2 blockade augments cancer immunotherapy

Zvi G. Fridlender, George Buchlis, Veena Kapoor, Guanjun Cheng, Jing Sun, Sunil Singhal, Cecilia Crisanti, Liang Chuan S Wang, Daniel Heitjan, Linda A. Snyder, Steven M. Albelda

Research output: Contribution to journalArticle

102 Scopus citations

Abstract

Altering the immunosuppressive microenvironment that exists within a tumor will likely be necessary for cancer vaccines to trigger an effective antitumor response. Monocyte chemoattractant proteins (such as CCL2) are produced by many tumors and have both direct and indirect immunoinhibitory effects. We hypothesized that CCL2 blockade would reduce immunosuppression and augment vaccine immunotherapy. Anti-murine CCL2/CCL12 monoclonal antibodies were administered in three immunotherapy models: one aimed at the human papillomavirus E7 antigen expressed by a non-small cell lung cancer (NSCLC) line, one targeted to mesothelin expressed by a mesothelioma cell line, and one using an adenovirus-expressing IFN-α to treat a nonimmunogenic NSCLC line. We evaluated the effect of the combination treatment on tumor growth and assessed the mechanism of these changes by evaluating cytotoxic T cells, immunosuppressive cells, and the tumor microenvironment. Administration of anti-CCL2/CCL12 antibodies along with the vaccines markedly augmented efficacy with enhanced reduction in tumor volume and cures of approximately half of the tumors. The combined treatment generated more total intratumoral CD8+ T cells that were more activated and more antitumor antigen-specific, as measured by tetramer evaluation. Another important potential mechanism was reduction in intratumoral T regulatory cells. CCL2 seems to be a key proximal cytokine mediating immunosuppression in tumors. Its blockade augments CD8 + T-cell immune response to tumors elicited by vaccines via multifactorial mechanisms. These observations suggest that combining CCL2 neutralization with vaccines should be considered in future immunotherapy trials.

Original languageEnglish (US)
Pages (from-to)109-118
Number of pages10
JournalCancer Research
Volume70
Issue number1
DOIs
StatePublished - Jan 1 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'CCL2 blockade augments cancer immunotherapy'. Together they form a unique fingerprint.

  • Cite this

    Fridlender, Z. G., Buchlis, G., Kapoor, V., Cheng, G., Sun, J., Singhal, S., Crisanti, C., Wang, L. C. S., Heitjan, D., Snyder, L. A., & Albelda, S. M. (2010). CCL2 blockade augments cancer immunotherapy. Cancer Research, 70(1), 109-118. https://doi.org/10.1158/0008-5472.CAN-09-2326